Jane Street’s Gyre Therapeutics GYRE Stock Holding History

Jane Street’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,000	Closed	-$70.6K	–	12128
2025 Q4	$70.6K	Buy	+10,000	New	+$77.2K	﹤0.01%	10368

Other funds holding GYRE

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Jane Street's GYRE Position: Q4 2025 in Review

Jane Street sold out of Gyre Therapeutics (GYRE) in Q4 2025, closing a stake of 12,958 shares — an estimated $100K sold.

Jane Street first reported a position in GYRE in Q2 2013 and held it in 10 quarters. The position peaked at $534K in Q1 2024. 44 funds tracked by Wall St. Rank hold GYRE as of Q4 2025.

Jane Street reported no remaining Gyre Therapeutics position as of Q4 2025 after selling out during the quarter.
Jane Street sold 12,958 Gyre Therapeutics shares in Q4 2025, an estimated $100K.
Jane Street first reported a position in Gyre Therapeutics in Q2 2013 and held it in 10 quarters.
Jane Street's Gyre Therapeutics position peaked at $534K in Q1 2024.
44 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2025.

Based on Jane Street's 13F filing for Q4 2025, filed 12 Feb 2026.